medigraphic.com

2004, Number S1

<< Back Next >>

Rev Mex Anest 2004; 27 (S1)

An update on genetic and perioperative patient management

Schwinn DA, Duke JB

Language: English
References: 16
Page: 71-75
PDF size: 92.09 Kb.


Text Extraction

LEARNING OBJECTIVES

1. Be able to describe genetic polymorphisms and how they may change proteins
2. Be able to describe the difference between background genetic changes and those that may have clinical impact
3. Describe how to begin planning for a genetic outcome study in the perioperative period


REFERENCES

  1. 1— Brandt A, Schleithoff L, Jurkat-Rott K, Klinger W, Baur C, Lehmann-Horn F. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999;8: 2055-2062.

  2. 2— Heusch G, Erbel R, Siffert W. Genetic determinants of coronary vasomotor tone in humans. Am J Physiol: Heart Circ Physiol 2001;281:H1465-1468.

  3. 3— Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997;49:369-379.

  4. 4— Liggett SB. Beta(2)-adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 2000;161:S197-201.

  5. 5— Liggett SB. Pharmacogenetic applications of the Human Genome project. Nat Med 2001;7:281-283.

  6. 6— Mathew JP, Rinder CS, Howe JG, Fontes M, Crouch J, Newman MF, Philips-Bute B, Smith BR. Platelet PlA2 polymorphism enhances risk of neurocognitive decline after cardiopulmonary bypass. Ann Thorac Surg 2001;71:663-666

  7. 7— McCarthy JJ, Hilfiker R. The use of single nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000;18:505-508.

  8. 8— Rathz DA, Gregory KN, Fang Y, Brown KM, Liggett SB. Hierarchy of polymorphic variation and desensitization permutations relative to beta-1 and beta-2 adrenergic signaling. J Biol Chem 2003;278:10784-10789.

  9. 9— Risch N, Merikangas K. Science 1996;273:1516-1517.

  10. 10— Rockman HA, Koch WJ, Lefkowitz RJ. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol 1997;272:H1553-1559-

  11. 11— Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing efficacy and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002;113:746-750.

  12. 12— Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-865.

  13. 13— Schwinn DA, Booth JV. Genetics infuses new life into human physiology: implications of the human genome project for anesthesiology and perioperative medicine. Anesthesiology 2002;96: 261-263.

  14. 14— Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nature Rev (Genetics) 2002;3:1-7.

  15. 15— Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-537.

  16. 16— Ziegeler S, Tsusaki BE, Collard CD. Influence of genotype on perioperative risk and outcome. Anesthesiology 2003;99:212-219.




2020     |     www.medigraphic.com